Global Leukemia therapeutics Market: Increased use of leukemia therapeutic due to rising number of cancer diseases across the world.

Published Date: 07/05/2021

The leukemia therapeutics market is projected to reach USD 19.98 billion by 2027 from USD 13.26 billion in 2020, at a CAGR of 6.0 % during the forecast period.Leukemia is defined as a cancer observed in white blood cell (WBC) in our body. White blood cell helps our body to fight against infection caused by harmful pathogen. Bone marrow is the center for the production of RBC (carry oxygen to all part of body), WBC (fight against infection) and platelets (help in blood clotting). Our bone marrow produces abnormal WBC when we are suffering from leukemia. Moreover abnormal WBCs are not able to perform normal functioning or WBC loses its ability to fight against infection. Etiology for leukemia includes artificial ionizing radiation, benzene and petrochemicals, alkylation chemotherapy agents, genetic predisposition and electromagnetic energy. Genetic predisposition and electromagnetic energy is the most common cause of leukemia observed among people. Signs and symptoms of leukemia includes a new lump or swollen gland in neck and arm, frequent nosebleed, pain in the bone, night sweat and frequent fever. Leukemia can be diagnosed by bone marrow tests, platelet count and WBC (white blood cell) differential count test. Leukemia can be treated by blood transfusion, immunotherapy, bone marrow transplantation, radiation therapy and chemotherapy.
Commercially available drug in the market for the treatment of leukemia includes Gleevec, Bosulif, Sprycel, Iclusig and others. Drugs which are in clinical trials expected to launch in the marketwithin next few (3 to 5)years include Bosutinib, Omapro, ga101/rg7159, Vidaza, Dacogen, Midostaurin, Vosaroxin, Quizartinib, Graspa, Marqibo.

In recent time there is increased use of leukemia therapeutic due to rising number of cancer diseases across the world. Rising aging population, lifestyle factors and increasing awareness for healthcare are some of the key driving factors for the growth of the global leukemia therapeutics market. In addition, innovative and targeted drug delivery is also fuelling the growth of the global leukemia therapeutics market. However, availability of large numbers of generic form of drugs and limited treatment options are some of the major factors restraining the growth of the global leukemia therapeutics market. In addition, high unmet need for diagnosis is also restraining the growth of the global leukemia therapeutics market.

Off label prescribing would support the growth of the global leukemia therapeutics market. In addition, limited number of market players would supports the entry of new market players. Innovative and safer therapies could develop an opportunity for growth of the global leukemia therapeutic market. However, adverse effect caused by chemotherapy and radiation therapy could lead a challenge for the global leukemia therapeutics market.

The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland), F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.

There has been a tremendous increase in cell-based research activities over the past decade. Increasing research in the field of regenerative medicine for the treatment of leukemia and growing awareness on personalized medicine have also resulted in the growth of this market. In addition to it, the growth in this market is driven by the high prevalence and incidence of leukemia and the rising geriatric population. According to the Leukemia& Lymphoma Society, an estimated 381,774 people are living with or in remission from leukemia in the US.

The Canadian government is taking various initiatives to support leukemia research and develop novel immunotherapies. For instance, in January 2016, the Canadian government announced the provision of USD 20 million to the Centre for Commercialization of Regenerative Medicine (CCRM) to help establish a stem cell therapy development facility in Toronto (Canada).